This collaboration aims to enhance Ribo’s target discovery capacity in cardiometabolic diseases by integrating human evidence generated through Pheiron’s AI technology.

PheironGPS systematically integrates human multi-omic data at scale to pinpoint biological mechanisms and drive actionable insights on targets and patient populations. This collaboration will establish a strong scientific connection between therapeutic targets and disease causality, offering unprecedented guidance for the clinical development of Ribo’s RNA-based therapeutics, the companies state.

“We can now access multi-omic information from both general and specific patient populations. We are delighted to collaborate with the highly skilled scientists at Pheiron. Their proprietary AI algorithms, combined with our experienced scientists and drug developers, will help unravel complex patho-physiological networks. This collaboration will increase our success rate in discovering novel biology and disease pathways linked to unmet medical needs in the cardiometabolic area,” says Li-Ming Gan, CEO of Ribocure Pharmaceuticals AB and co-CEO of Suzhou Ribo Life Science, Ltd.

Suzhou Ribo Life Science Ltd and Ribocure Pharmaceuticals

Suzhou Ribo Life Science Ltd is a clinical stage biotech company dedicated to advancing the field of cutting-edge RNA therapeutics. Ribocure Pharmaceuticals AB is the international research center of Suzhou Ribo Life Science Ltd.